Radioactive drug for DLL3-positive lung and prostate cancers
Part of Cancer clinical trials.
This early-phase trial tests a new radioactive drug that targets a protein (DLL3) found on some lung and prostate cancer cells. It aims to see if this drug is safe and effective for patients whose cancer has progressed after standard treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of lung or prostate cancer that is high-grade and has spread, and it must have gotten worse after at least one round of standard chemotherapy.
- You must have a tumor that is at least 2 cm (about the size of a grape) that can be seen on a CT or MRI scan.
- You must have a protein called DLL3 on your tumor, which the study drug targets. This is checked with a special scan or biopsy.
- You must be 18 years or older and able to give informed consent.
- Your cancer must show signs of growth (like new lesions or a 20% increase in size) within 3 months of starting the study.
- You must have adequate organ function (blood counts, kidney, liver) and be willing to use effective birth control if you can have children.
- You must be willing to have biopsies (tissue samples) taken before and during the study.
- You cannot have untreated or unstable brain metastases, or be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a special PET/CT imaging scan that may help doctors find where small cell lung cancer (and some related tumors) are in the body using a DLL3 target. It’s a Phase 1/2 study, mainly to see how well the scan detects tumors and guides care.
This trial tests a new radioactive drug called [177Lu]Lu-DFC413 for people with certain advanced solid tumors that have stopped responding to standard treatments. The drug is designed to target cancer cells with a specific marker seen on a special scan.
This trial tests an experimental treatment using your own immune cells, modified to better find and attack cancer cells that carry a marker called DLL3. It is for people with certain neuroendocrine tumors, including small cell lung cancer, who have already tried standard treatments.
This trial uses a special PET/CT scan that targets a substance called DLL3, found on some cancer cells, to see if doctors can better detect or monitor neuroendocrine carcinoma. It may help you and your doctor get clearer information about your cancer.
This trial tests an experimental treatment for several types of advanced cancer that have stopped responding to standard therapy. The drug targets a protein called DLL3 found on some tumor cells, which may help slow or stop tumor growth.
This study tests a new type of PET/CT scan that looks for a marker called DLL3 on neuroendocrine cancer cells. It aims to see if this scan finds tumors better than standard scans, which could help guide treatment.
Hear when a new Neuroendocrine Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.